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Abstract
Background
Gestational diabetes mellitus (GDM) is an increasingly prevalent risk factor for type 2 diabe-
tes. We evaluated the effectiveness of a group-based lifestyle modification program in
mothers with prior GDM within their first postnatal year.
Methods and Findings
In this study, 573 women were randomised to either the intervention (n = 284) or usual care
(n = 289). At baseline, 10% had impaired glucose tolerance and 2% impaired fasting glu-
cose. The diabetes prevention intervention comprised one individual session, five group
sessions, and two telephone sessions. Primary outcomes were changes in diabetes risk
factors (weight, waist circumference, and fasting blood glucose), and secondary outcomes
included achievement of lifestyle modification goals and changes in depression score and
cardiovascular disease risk factors. The mean changes (intention-to-treat [ITT] analysis)
over 12 mo were as follows: −0.23 kg body weight in intervention group (95% CI −0.89,
0.43) compared with +0.72 kg in usual care group (95% CI 0.09, 1.35) (change difference
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−0.95 kg, 95% CI −1.87, −0.04; group by treatment interaction p = 0.04); −2.24 cm waist
measurement in intervention group (95% CI −3.01, −1.42) compared with −1.74 cm in usual
care group (95% CI −2.52, −0.96) (change difference −0.50 cm, 95% CI −1.63, 0.63; group
by treatment interaction p = 0.389); and +0.18 mmol/l fasting blood glucose in intervention
group (95% CI 0.11, 0.24) compared with +0.22 mmol/l in usual care group (95% CI 0.16,
0.29) (change difference −0.05 mmol/l, 95% CI −0.14, 0.05; group by treatment interaction
p = 0.331). Only 10% of women attended all sessions, 53% attended one individual and at
least one group session, and 34% attended no sessions. Loss to follow-up was 27% and
21% for the intervention and control groups, respectively, primarily due to subsequent preg-
nancies. Study limitations include low exposure to the full intervention and glucose metabo-
lism profiles being near normal at baseline.
Conclusions
Although a 1-kg weight difference has the potential to be significant for reducing diabetes
risk, the level of engagement during the first postnatal year was low. Further research is
needed to improve engagement, including participant involvement in study design; it is
potentially more effective to implement annual diabetes screening until women develop pre-
diabetes before offering an intervention.
Trial Registration
Australian New Zealand Clinical Trials Registry ACTRN12610000338066
Author Summary
WhyWas This Study Done?
• Women who have had gestational diabetes are much more likely to develop type 2
diabetes.
• Although many diabetes prevention programs for people over the age of 50 exist, few are
tailored to the needs of young mothers who have had gestational diabetes.
• On the assumption that offering prevention earlier is beneficial, researchers developed
and tested a diabetes prevention program for women who had gestational diabetes;
women participated in the program during their first year after giving birth.
What Did the Researchers Do and Find?
• The researchers enrolled 573 women in a one-year study: 284 women were assigned to
the diabetes prevention program (one individual session and five group sessions over a
three-month period, followed by telephone calls at six and nine months), and 289 were
assigned to the control group (usual postnatal care).
• After one year, the average changes for women in the diabetes prevention program were
a 0.23-kg decrease in weight, a 2.24-cm decrease in waist circumference, and a 0.18-
mmol/l increase in fasting blood glucose, while the average changes for women in the
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control group were a 0.72-kg increase in weight, a 1.74-cm decrease in waist circumfer-
ence, and a 0.22-mmol/l increase in fasting blood glucose. The between-group difference
in weight change was 0.95 kg.
• The number of women who attended the diabetes prevention program was lower than
anticipated—10% attended all sessions, and 53% attended the individual session plus at
least one group session; about a quarter of women did not complete the study, mainly
due to becoming pregnant again.
What Do These Findings Mean?
• These findings suggest that although a diabetes prevention program designed for
women who have had gestational diabetes can prevent weight gain over 12 months, get-
ting women to engage with the program was challenging, so it would not be sustainable
in routine health services.
• The women who participated in the study had low diabetes risk profiles (only one in ten
had impaired glucose tolerance), and most diabetes prevention guidelines would not cat-
egorise them as being at sufficiently high risk for participation in a diabetes prevention
program.
• For diabetes prevention programs in women who have had gestational diabetes, further
research is required on the process of engagement and lifestyle interventions at other
time points, including participant involvement in the design of interventions. Australian
clinical guidelines stipulate that women who have had gestational diabetes should be
screened annually for diabetes. One option for management would be to wait until they
develop prediabetes before offering a diabetes prevention program, which may prove
more effective because their children will be older and women may be easier to engage
in improving their health.
Introduction
Gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) rates are rising
worldwide [1], posing an increasing burden on the health and economic welfare of nations [2].
Women with GDM are seven times more likely to develop T2DM than women who have nor-
moglycemic pregnancies [3]. Diabetes prevention is possible; two landmark studies in high risk
individuals from the general population showed that T2DM incidence could be reduced by
58% with a combination of weight loss and moderate physical activity [4,5]. The lifestyle modi-
fication program for the original US Diabetes Prevention Program (US-DPP) was imple-
mented over a 24-wk intensive intervention period with 16 individual coaching sessions, and a
maintenance period with individual sessions every 2 mo for 24 mo [6]. Positive prevention out-
comes (50% reduction in risk) were found for women with previous GDM within a subgroup
analysis of the US-DPP [7].
Given that women with prior GDM are at high risk of developing T2DM and cardiovascular
disease earlier in their lifespan than women with normoglycemic pregnancies [8], intervening
early with a suitable diabetes prevention program (DPP) has the potential to yield positive
health outcomes. Interpregnancy weight gain contributes to an increased risk of adverse preg-
nancy outcomes for both mother and baby during subsequent pregnancies [9,10], and the
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children of women with GDM are at increased risk of obesity and T2DM later in life [8].
Reducing postpartum weight retention decreases perinatal complications [10] and T2DM risk
[11,12] and can influence the health status of a woman’s children [13,14], but designing inter-
ventions for this life stage is challenging [15,16]. It is well recognised that many barriers exist
to mothers engaging in behaviour change during the early infancy period, including tiredness,
lack of time, competing work and carer duties, and cultural expectations [17–19]. It is unclear
the extent to which these obstacles can be overcome with a lifestyle modification program spe-
cifically designed to meet the needs of this population, as trials thus far have reported inconsis-
tent results [7,20–26].
The Mothers After Gestational Diabetes in Australia Diabetes Prevention Program (MAG-
DA-DPP) study was undertaken to test the effectiveness of a group-based lifestyle modification
program offered in the first postnatal year to women with previous GDM. At the time of MAG-
DA-DPP design, evidence on the optimal intervention was gathered [27], and Greater Green
Triangle Diabetes Prevention Program (GGT-DPP) [28] content was adapted to meet known
barriers and characteristics of the participant life stage. The program aimed to promote
changes, relative to usual care, in anthropometric, behavioural, and biomedical outcomes
[29,30].
Methods
Study Design
MAGDA-DPP was a multicentre, prospective, open randomised controlled trial (RCT) to
assess the effectiveness of a structured DPP for women with previous GDM. The detailed meth-
ods and research design of MAGDA-DPP are described elsewhere [29,30]. The trial recruited
women from two Australian state capital cities, Melbourne and Adelaide. The study was
approved by the relevant ethics committees and registered prospectively as an RCT. The co-
primary outcomes for MAGDA-DPP were change in fasting blood glucose, waist circumfer-
ence, and weight at 12 mo.
Participants
Women aged18 y with a diagnosis of GDM in their most recent pregnancy were eligible for
inclusion. GDM was defined by Australasian Diabetes in Pregnancy Society (ADIPS) criteria
[31] at the time of study commencement: fasting plasma glucose (FPG) of 5.5 mmol/l or
higher, or 2-h glucose of 8.0 mmol/l or higher on a 75-g oral glucose tolerance test (OGTT), or
a glucose challenge test result of 11.1 mmol/l or higher. Exclusion criteria were the following:
preexisting diabetes (type 1 diabetes mellitus or T2DM); cancer (not in remission); severe men-
tal illness; substance abuse (illicit drugs); myocardial infarction in the preceding 3 mo; difficulty
with English; involvement in another postnatal intervention trial; and pregnancy at postnatal
baseline testing or at any point during the 12 mo of study involvement. Women diagnosed
with T2DM or who became pregnant during the study were excluded based on the influence
their condition would have on the primary outcome measures of weight, waist circumference,
and FPG.
Recruitment
MADGA-DPP used multiple recruitment strategies, prospective and retrospective, which are
described in full within our methodology publications [29,30]. Briefly, prospective recruitment
involved approaching women in the antenatal clinic soon after the diagnosis of GDM, at
around 28 wk of pregnancy, and conducting eligibility screening. Eligible women were
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provided with a patient information and consent form to return via prepaid envelope within 4
wk. If consent forms were not received within that time frame, follow-up contact was made
with the woman. Once consent was received, the woman was contacted at 3 mo postpartum to
initiate baseline testing.
The National Diabetes Services Scheme (NDSS) is an Australian Government initiative to
subsidise blood glucose monitoring supplies for people with diabetes and is in effect a national
diabetes registry. Women who have had GDM are recorded in a subregistry of the NDSS called
the National Gestational Diabetes Register (NGDR). Retrospective recruitment occurred using
the following approaches: a mail-out via the NDSS (using data from the NGDR) to women liv-
ing in relevant postcodes in Adelaide (South Australia) and Melbourne (Victoria); referrals
from one private obstetrician (South Australia); and hospital records database mining (South
Australia). Women who had GDM diagnosed during their most recent pregnancy were
approached and screened for eligibility using the predefined inclusion and exclusion criteria.
Written informed consent was obtained from all participants, regardless of recruitment
method, once screening confirmed their eligibility. The MAGDA-DPP commenced recruit-
ment 17 January 2011, and the last participant completed final testing 28 May 2015.
Data Collection
Following signed consent, a trained research nurse conducted the study assessments in the par-
ticipant’s home. All participants completed a baseline assessment, and the assessment was
repeated after 12 mo. Standardised protocols for all clinical measures (blood pressure, anthro-
pometry, blood sampling) were implemented [32]. Blood samples were collected by the study
nurse/phlebotomist and analysed by Melbourne Pathology (Victoria) or Clinpath Laboratories
(South Australia). The study nurse conducted the anthropometric (height, weight, waist cir-
cumference) and blood pressure measurements. Women provided fasting venous samples for
lipid (triglycerides, total cholesterol, low-density lipoprotein cholesterol [LDL-C] and high-
density lipoprotein cholesterol [HDL-C]), HbA1c, and glucose (fasting and 2-h OGTT) analy-
sis. In addition to the baseline and 12-mo assessments, the intervention group repeated all
blood tests (except OGTT) and weight and waist measures at 3 mo after baseline testing or as
soon as possible after their final MAGDA-DPP group session. Survey data were completed at
baseline and 12 mo and included the questions about the following: demographics (breastfeed-
ing, parity, education, employment status, cultural background; baseline only); diet (Food Fre-
quency Questionnaire [33]); physical activity (Active Australia Questionnaire [34]); self-
regulation and self-efficacy for diet and physical activity (not reported); social support (Multi-
dimensional Scale of Perceived Social Support; not reported); quality of life (Assessment of
Quality of Life 8D; not reported); depressive symptoms and suicidal ideation (Patient Health
Questionnaire 9 [PHQ-9]); and health status (including smoking status and history of diabetes,
myocardial infarction, cancer, and mental disorders). Health status information on history of
diabetes, myocardial infarction, cancer, and mental disorders was collected at baseline for
checking of exclusion criteria. All women completing clinical testing were provided with a
standardised feedback letter on their test results, and a copy was sent to their nominated family
physician.
The MAGDA-DPP adopted the lifestyle modification goals of the Finnish Diabetes Preven-
tion Study (FIN-DPS) [35] for the intervention program content and messaging. The MAG-
DA-DPP had five lifestyle modification goals:30% of energy from fat,10% of energy from
saturated fat,15 g dietary fibre per 1,000 kcal,30 min of moderate physical activity daily,
and5% body weight reduction. The first three goals were calculated using Food Frequency
Questionnaire data [33], the fourth using Active Australia Questionnaire data [34], and the
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fifth using actual body weight. In the FIN-DPS, the number of lifestyle modification goals
achieved was inversely associated with diabetes incidence over a 13-y period [5].
Randomisation
The trial was registered with the Australian New Zealand Clinical Trials Registry on 28 April
2010, and the first participant was randomised on 1 August 2011. Once baseline diabetes
screening (OGTT) results were known, eligible women were randomly allocated into either the
intervention or control arm using the MAGDA-DPP management database. Permuted block
randomisation was stratified by recruitment location and method. A sequence number was dis-
played, and the assignment code (usual care or intervention) revealed to the user in the rando-
misation office at Deakin University.
Diabetes Prevention Program
After randomisation, the active intervention consisted of one individual and five group sessions
delivered by specially trained healthcare professionals, with two additional follow-up mainte-
nance telephone calls for each participant, as shown in S1 Fig. As previously described [29,30],
the lifestyle intervention was informed by a theoretical framework based on the Health Action
Process Approach and supported by social cognitive and self-regulation theory [36]. The inter-
vention was based on the GGT-DPP, which was previously shown to be effective in producing
change in diabetes risk factors [28]. The MAGDA-DPP was tailored to reflect relevant barriers
for mothers of young children (for example, topics covered the impact of sleep deprivation,
stress management and mindful eating, healthy eating for families, weaning, culturally appro-
priate and cost- and time-saving food preparation, and exercise considerations when caring for
young children), and mothers were able to bring their children along to group sessions.
Fidelity measures were incorporated throughout the intervention (facilitator manual,
detailed training program, and audio recording of all facilitator sessions). The first DPP session
(the individual session) was delivered in the woman’s home by the facilitator, and the MAG-
DA-DPP handbook was provided. The session focus was on the intention formation compo-
nent of the Health Action Process Approach, personalisation of T2DM risk using a risk
algorithm, and individual goal setting. This was followed by five group sessions held at 2-wk
intervals and two subsequent individual phone calls at 3 and 6 mo after the final group session.
Each group session was approximately 2 h in duration, with up to 15 women per group. Session
content details are reported in the protocol paper [30]. Women were encouraged to set and
review at least one personal goal relating to diet and one relating to physical activity at each
program session (Box 1). Women in the control group received usual care and were offered the
intervention program after their 12-mo final assessment.
Program Evaluation
The penetration, implementation, participation, and effectiveness (PIPE) framework for evalu-
ating real-world program and product design elements important to implementation is a met-
ric to evaluate the net impact of health improvement programs [37]. Four elements make up
the PIPE metrics: penetration of the program into the population of interest; implementation
of the proposed set of services; participation in the program; and effectiveness in generating
expected outcomes. Penetration is defined as the number of individuals reached/invited
divided by the number of individuals in the target population. According to Aziz et al. [37],
penetration of 33% or lower is considered low, 34%–66% as moderate, 67% or higher as high.
Program implementation is rated on three aspects: frequency of contact, duration of the inter-
vention, and fidelity measures. Frequency of contact is defined based on the number, length,
Postnatal Diabetes Prevention Randomised Trial
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Box 1. MAGDA-DPP Intervention Components
Intensive Phase
Individual session (delivered in participant’s home): DPP overview, personal-
ised participant T2DM risk assessment, five lifestyle modification goals described, build-
ing participant commitment, personalised diet and physical activity goal setting with
participant.
Group session 1 (community venue within 1 mo of individual session):
Understanding diabetes and diabetes risk factors, knowledge and skill building on the
topic of saturated fat, family-focused activities on reducing saturated fat content in diet,
review of personalised goals and group goal setting for next 2 wk.
Group session 2 (community venue 2 wk after group session 1): Knowledge
and skill building on modifying the total fat content of participants’ diet, discussion on
postpartum weight management, learning activities focused on reducing fat content in
diet for whole family, review of personalised goals and group goal setting for next 2 wk.
Group session 3 (community venue 2 wk after group session 2): Knowledge
and skill building on increasing the fibre content of participants’ diet, learning activities
focused on healthier food shopping and getting more fibre into the whole family’s diet
and meals, review of personalised goals and group goal setting for next 2 wk.
Group session 4 (community venue 2 wk after group session 3): Knowledge
and skill building on healthier meal planning, learning activities focused on negotiating
stressful situations around food choice with family members and mindful eating, knowl-
edge and skill building on good sleep hygiene, review of personalised goals and group
goal setting for next 2 wk.
Group session 5 (community venue 2 wk after group session 4): Knowledge
and skill building on postnatal depression awareness and stress management, discussion
on lifestyle modification relapse prevention and change maintenance, review of personal-
ised goals and group longer-term goal setting.
Maintenance Phase
Telephone session 1 (3 mo after group session 5): Review of progress and lon-
ger-term goal setting.
Telephone session 2 (6 mo after group session 5): Review of progress and lon-
ger-term goal setting.
Postnatal Diabetes Prevention Randomised Trial
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and type of contact within the first 12 mo of a program. A group or individual contact counts
as one session, an online/telephone contact counts as 0.5 of a session, and a text/email/fax con-
tact counts as 0.25 of a session. The total number of sessions is divided by the number of ses-
sions delivered within the US-DPP (22 sessions) to calculate frequency (33% low, 34%–66%
moderate,67% high). Interventions lasting less than 6 mo are defined as low duration, 6–12
mo as moderate duration, and more than 12 mo as high duration. Fidelity is rated as follows:
no standard curriculum as low, standard curriculum but no quality assurance measures
reported as moderate, and a standard curriculum and quality assurance measures reported as
high. Participation is the number of individuals enrolled in the intervention divided by the
number of individuals reached/invited (33% low, 34%–66% moderate,67% high). For
DPPs, effectiveness is rated on three criteria: outcome success (number of participants achiev-
ing the main outcome divided by total number of participants completing intervention, where
25% low, 26%–40% moderate,>40% high success), average weight loss (2.3 kg low, 2.4–4.6
kg moderate,>4.6 kg high), and absolute/relative risk reduction (15% low, 16%–30% moder-
ate,>30% high).
Statistical Analysis
Analyses of primary and secondary endpoints were performed using SPSS version 22 and inde-
pendently verified in GenStat release 16.1. Participants’ baseline characteristics are presented
as summary measures. A statistical analysis plan was prepared, finalised, and signed off by the
project guarantor prior to statistician unblinding. Analyses were carried out for all participants
randomised to the study (ITT set, n = 573) and for the per protocol set (PPS, n = 331). The PPS
analysis was confined to the subset of ITT participants excluding those with major protocol
deviations such as allocation to the intervention but no exposure to any intervention sessions
or ineligibility. Protocol deviations were determined independently of, and prior to, the
unblinding of the trial statistician. PPS exclusions included post-baseline assessments beyond
the specified time window (n = 2), pregnancy (n = 75), randomised to control group but
received the intervention (n = 1), participation in another postnatal intervention during the
trial (n = 3), should not have been randomised to trial (T2DM at baseline, n = 1), diagnosed
with T2DM during trial (n = 11), lost contact or moved away or overseas (n = 48), and with-
drew (n = 19). Similar proportions of women in the usual care and intervention arms—14%
(40/289) and 12% (35/284), respectively—became pregnant during the trial. Also excluded
from the PPS were women who did not receive minimum exposure to the intervention
(n = 78). Minimum exposure was defined in the statistical analysis plan as attending the indi-
vidual session and at least one group session.
Mixed model analyses of continuous scale endpoints used the residual maximum likelihood
(REML) method to cope with missing values. The significance of the F-test for the group by
time interaction is reported, as well as t-tests for within-group changes over time and between-
group differences at each time point. The proportion of participants in each group known to
have achieved each of the first four lifestyle modification goals at baseline and 12 mo was calcu-
lated, and the method of generalised estimating equations was used to fit models to enable
group by time interactions to be tested (Wald chi-squared test). Lifestyle modification goal 5
(5% body weight reduction at 12 mo) was assessed using a two-sample binomial test to com-
pare the proportions in each group. The number of goals achieved (0 to 5) by individuals at 12
mo was assessed using a mixed model analysis. Sensitivity analyses, in which missing assess-
ments were deemed to indicate unmet goals, were conducted for each goal and also for the
combined score. Unless otherwise stated, all statistical tests were conducted at the 5% signifi-
cance level, with no adjustments for multiplicity of either endpoints or comparisons.
Postnatal Diabetes Prevention Randomised Trial
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The required sample size, using a two-sided 5% significance level and 80% power, was 574
(287 in each arm); this was based on the co-primary endpoint with the smallest conjectured
effect size, namely, the change in FPG over 12 mo in the GGT-DPP study [28], and thus the
study was powered to detect an effect size of0.27 mmol/l (assuming a mean difference
between the intervention and control groups of 0.14 mmol/l and a within-group standard devi-
ation of 0.5 mmol/l). The sample size was increased to allow for an attrition rate of up to 25%.
Results
Participants
We approached 8,031 women, either face-to-face or via mailed out invitation, and of those,
2,211 (28%) were screened for eligibility. Of these, 828 women (38%) consented to participate
in the trial, and 573 (69%) were randomised. It took 41 mo to recruit and randomise the 573
participants. The trial flow for MAGDA-DPP is shown in Fig 1. While 28% and 38% of partici-
pants were overweight or obese, respectively, the level of impaired glucose metabolism was low
in the cohort (n = 58 [10%] with impaired fasting glucose; n = 10 [2%] with impaired glucose
tolerance [IGT]). The intervention and usual care groups were comparable in their baseline
characteristics (Table 1). The mean age of participants’ infants at baseline was 8.0 mo (standard
deviation 4.8). The number of women excluded from the PPS analysis was different between
the groups (n = 164 [58%] intervention participants excluded; n = 78 [27%] control partici-
pants excluded), and this difference remained significant when exclusion for not meeting mini-
mum program exposure was removed (n = 139 [49%] intervention participants excluded;
n = 78 [27%] control participants excluded). Retention rates for the intervention and usual care
groups were 73% and 79%, respectively. When pregnancy was removed from loss to follow-up
data, the retention rates were 93% for the usual care group and 85% for the intervention group.
A single adverse event was recorded within the study (needle stick trauma), but this occurred
during screening and prior to randomisation.
Fig 1. Trial flow using CONSORT reporting. ITT and PPS participants reported following randomisation.
IS, individual session; loss, loss to follow-up.
doi:10.1371/journal.pmed.1002092.g001
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Table 1. Baseline characteristics by treatment condition in the MAGDA-DPP study.
Characteristic Control (n = 289) Intervention (n = 284) All Participants (n = 573)
Age (years)
N 287 281 568
Mean (standard deviation) 33.6 (5.1) 34.1 (5.3) 33.8 (5.2)
Waist circumference (cm)
N 289 283 572
Mean (standard deviation) 90.4 (14.5) 92.1 (14.4) 91.2 (14.5)
BMI
N 288 281 569
Mean (standard deviation) 28.4 (6.7) 29.2 (6.9) 28.8 (6.8)
Weight (kg)
N 289 284 573
Mean (standard deviation) 74.6 (20.3) 76.7 (20.0) 75.6 (20.2)
Physical activity (min/d) 35.1 (42.9) 33.4 (43.7) 34.3 (42.9)
Energy intake (kcal/d) 1,899 (860) 1,860 (799) 1,880 (816)
Energy from total fat (percent/d) 37.9 (5.2) 38.1 (5.3) 38.0 (5.2)
Fibre intake (g/d) 20.6 (8.8) 20.4 (8.2) 20.5 (8.5)
Haemoglobin A1c (percent)
N 289 283 572
Mean (standard deviation) 5.34 (0.45) 5.34 (0.39) 5.34 (0.42)
OGTT (mmol/l)
N 289 282 571
Fasting glucose 4.72 (0.52) 4.82 (0.54) 4.77 (0.53)
2-h glucose 5.55 (1.60) 5.53 (1.67) 5.54 (1.63)
Tertiary education 237 (82.6%) 237 (84.3%) 474 (83.5%)
Income
Low 57 (20.0%) 71 (25.5%) 128 (22.7%)
Medium 133 (46.7%) 119 (42.8%) 252 (44.8%)
High 95 (33.3%) 88 (31.7%) 183 (32.5%)
Current smoker 21 (7.3%) 11 (3.9%) 32 (5.6%)
Full-time employed 49 (17.0%) 46 (16.2%) 95 (16.6%)
Depressive symptoms (PHQ-9)
Minimal depression (score 0–9) 254 (88.8%) 256 (90.5%) 510 (89.6%)
Moderate depression (score 10–19) 31 (10.8%) 27 (9.5%) 58 (10.2%)
Severe depression (score 20–27) 1 (0.3%) 0 (0.0%) 1 (0.2%)
Breastfeeding initiated 259 (90.2%) 238 (84.7%) 497 (87.5%)
Parity
1 126 (43.9%) 127 (45.2%) 253 (44.5%)
2 97 (33.8%) 97 (34.5%) 194 (34.2%)
3+ 64 (22.3%) 57 (20.3%) 121 (21.3%)
Cultural background by geo-region
Africa 13 (4.5%) 7 (2.5%) 20 (3.5%)
Americas 1 (0.3%) 3 (1.1%) 4 (0.7%)
Asia 110 (38.1%) 113 (39.8%) 223 (38.9%)
Europe 95 (32.9%) 71 (25.0%) 166 (29.0%)
Oceania 3 (1.0%) 4 (1.4%) 7 (1.2%)
Australia and New Zealand 58 (20.1%) 73 (25.7%) 131 (22.9%)
Aboriginal and Torres Strait Islander 0 (0.0%) 1 (0.4%) 1 (0.2%)
(Continued)
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Primary Outcomes
The intervention group’s mean weight change was −0.23 kg (95% CI −0.89, 0.43) compared
with +0.72 kg (95% CI 0.09, 1.35) in the usual care group (change difference −0.95 kg, 95% CI
−1.87, −0.04; group by treatment interaction p = 0.04) over 12 mo. The intervention group’s
mean change in waist circumference was −2.24 cm (95% CI −3.01, −1.42) compared with
−1.74 cm (95% CI −2.52, −0.96) in the usual care group (change difference −0.50 cm, 95% CI
−1.63, 0.63; group by treatment interaction p = 0.389) over 12 mo. The intervention group’s
mean increase in fasting blood glucose was 0.18 mmol/l (95% CI 0.11, 0.24) compared with an
increase of 0.22 mmol/l (95% CI 0.16, 0.29) in the usual care group (change difference −0.05
mmol/l, 95% CI −0.14, 0.05; group by treatment interaction p = 0.331) over 12 mo. Tables 2
and 3 show the results for the ITT analysis set for the 12-mo data; no other statistically sig-
nificant results were identified across the primary and secondary endpoints when using the
F-test of the group by time interaction—a result that was consistent for both the ITT and PPS
analyses.
Intervention Group Changes
Compared with baseline levels, the between-time comparisons at 3 mo show that mean weight
change in the intervention group was −0.92 kg (p = 0.001) (Table 4). Other significant results
in the intervention arm at 3 mo were a reduction in waist circumference, total cholesterol,
Table 1. (Continued)
Characteristic Control (n = 289) Intervention (n = 284) All Participants (n = 573)
Unknown 9 (3.1%) 12 (4.2%) 21 (3.7%)
Data are presented as N, mean (standard deviation), or n (percent).
doi:10.1371/journal.pmed.1002092.t001
Table 2. Two-way table of predictedmeans (standard errors) and differences of means (p-values) for the co-primary endpoints of weight, waist cir-
cumference, and fasting blood glucose by treatment condition and time (intention-to-treat analysis).
Outcome Control Intervention Difference
Weight (kg) (p = 0.041)1
Baseline2 74.61 (1.22) 76.67 (1.23) 2.05 (0.238)
12 mo3 75.34 (1.23) 76.44 (1.25) 1.10 (0.531)
Difference 0.72 (0.024) −0.23 (0.498)
Waist (cm) (p = 0.389)1
Baseline4 90.36 (0.87) 92.10 (0.87) 1.74 (0.158)
12 mo5 88.62 (0.88) 89.86 (0.90) 1.24 (0.326)
Difference −1.74 (<0.001) −2.24 (<0.001)
FPG (mmol/l) (p = 0.331)1
Baseline2 4.72 (0.03) 4.82 (0.03) 0.10 (0.049)
12 mo6 4.94 (0.04) 4.99 (0.04) 0.05 (0.357)
Difference 0.22 (<0.001) 0.18 (<0.001)
1p-Value for the F-test of the time by treatment interaction.
2Control n = 289, intervention n = 284.
3Control n = 228, intervention n = 206.
4Control n = 289, intervention n = 283.
5Control n = 227, intervention n = 206.
6Control n = 227, intervention n = 205.
doi:10.1371/journal.pmed.1002092.t002
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HDL-C, and LDL-C (all p< 0.001). FPG was significantly higher at 3 mo than at baseline (p<
0.001) (Table 4). Reductions in waist circumference, total cholesterol, HDL-C, and LDL-C
were maintained at 12 mo but not the reduction in weight. The increase in FPG persisted at 12
mo.
Lifestyle Modification Goals
Analysis of the proportion of participants meeting the MAGDA-DPP lifestyle modification
goals adopted from the FIN-DPS did not reveal any significant time by group interactions.
Similarly, there was no significant difference in the total number of goals achieved between the
two groups (Table 5). S2 Fig. displays the association between average weight loss and different
levels of engagement within the active intervention period (first 3 mo) and at 12 mo.
Table 3. Two-way table of predictedmeans (standard errors) and differences of means (p-values) for the secondary endpoints of blood pressure,
blood lipids, and depressive symptoms by treatment condition and time (intention-to-treat analysis).
Outcome Control Intervention Difference
OGTT 2-h glucose (mmol/l) (p = 0.605)1
Baseline 5.55 (0.10) 5.53 (0.10) −0.02 (0.910)
12 mo 5.64 (0.11) 5.54 (0.12) −0.10 (0.518)
Difference 0.10 (0.408) 0.01 (0.939)
Systolic blood pressure (mm Hg) (p = 0.526)1
Baseline 110.52 (0.70) 112.23 (0.71) 1.71 (0.087)
12 mo 111.55 (0.76) 112.61 (0.79) 1.05 (0.338)
Difference 1.03 (0.148) 0.38 (0.610)
Diastolic blood pressure (mm Hg) (p = 0.721)1
Baseline 70.15 (0.56) 71.56 (0.57) 1.41 (0.080)
12 mo 71.62 (0.61) 72.74 (0.63) 1.12 (0.203)
Difference 1.47 (0.008) 1.18 (0.042)
Total cholesterol (mmol/l) (p = 0.427)1
Baseline 5.14 (0.06) 5.06 (0.06) −0.08 (0.335)
12 mo 4.87 (0.06) 4.74 (0.06) −0.13 (0.124)
Difference −0.27 (<0.001) −0.32 (<0.001)
Triglycerides (mmol/l) (p = 0.379)1
Baseline 1.16 (0.04) 1.24 (0.04) 0.08 (0.140)
12 mo 1.22 (0.04) 1.26 (0.04) 0.04 (0.550)
Difference 0.06 (0.069) 0.02 (0.595)
LDL-C (mmol/l) (p = 0.417)1
Baseline 3.07 (0.05) 3.01 (0.05) −0.07 (0.341)
12 mo 2.92 (0.05) 2.81 (0.05) −0.12 (0.126)
Difference −0.15 (<0.001) −0.20 (<0.001)
HDL-C (mmol/l) (p = 0.217)1
Baseline 1.54 (0.02) 1.47 (0.02) −0.07 (0.030)
12 mo 1.40 (0.02) 1.36 (0.02) −0.04 (0.278)
Difference −0.14 (<0.001) −0.11 (<0.001)
Depressive symptoms (PHQ-9) (p = 0.132)1
Baseline 4.57 (0.23) 4.06 (0.23) −0.51 (0.111)
12 mo 4.39 (0.25) 4.41 (0.26) 0.03 (0.943)
Difference −0.19 (0.449) 0.35 (0.172)
1p-Value for the F-test of the time by treatment interaction.
doi:10.1371/journal.pmed.1002092.t003
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Program PIPE and Process Evaluation
The MAGDA-DPP intervention was delivered via an RCT and did not have a specific target
population for which penetration could be exactly calculated due to different recruitment
streams. Some idea of penetration can be estimated from the NDSS mail-out invitation to par-
ticipate, which was sent to 5,349 women registered with the NGDR and living in the study’s
Table 4. Predictedmeans (standard errors) of primary and secondary endpoints for participants in the intervention group at baseline, 3 mo, and
12mo.
Outcome1 Baseline 3 mo 12 mo Baseline versus 3 mo Baseline versus 12 mo 3 mo versus 12 mo
Weight (kg) (p = 0.002) 76.67 (1.22) 75.75 (1.23) 76.49 (1.23) 0.001 0.522 0.010
Waist (cm) (p < 0.001) 92.10 (0.89) 89.71 (0.91) 90.00 (0.91) <0.001 <0.001 0.435
FPG (mmol/l) (p < 0.001) 4.82 (0.03) 4.97 (0.04) 5.00 (0.04) <0.001 <0.001 0.513
Total cholesterol (mmol/l) (p < 0.001) 5.06 (0.05) 4.79 (0.06) 4.74 (0.06) <0.001 <0.001 0.257
Triglycerides (mmol/l) (p = 0.771) 1.24 (0.04) 1.26 (0.04) 1.26 (0.04) 0.532 0.554 0.971
LDL-C (mmol/l) (p < 0.001) 3.01 (0.05) 2.83 (0.05) 2.81 (0.05) <0.001 <0.001 0.538
HDL-C (mmol/l) (p < 0.001) 1.47 (0.02) 1.40 (0.02) 1.37 (0.02) <0.001 <0.001 0.033
1p-Value for the F-test of the time main effect.
doi:10.1371/journal.pmed.1002092.t004
Table 5. Proportion of participants meeting the lifestyle modification goals in the MAGDA-DPP study at baseline and 12 mo, and total number of
goals achieved at 12 mo (intention-to-treat analysis).
Lifestyle Modiﬁcation Goal Control Intervention p-Value
30% of energy from fat
Baseline 23/287 (8.01%) 22/281 (7.83%) 0.966
12 mo 20/221 (9.05%) 25/204 (12.25%) 0.292
p-Value 0.544 0.070 0.3661
10% of energy from saturated fat
Baseline 14/287 (4.88%) 17/281 (6.05%) 0.538
12 mo 12/221 (5.43%) 16/204 (7.84%) 0.264
p-Value 0.912 0.416 0.6361
15 g/1,000 kcal ﬁbre intake
Baseline 31/287 (10.80%) 33/281 (11.74%) 0.752
12 mo 28/221 (12.67%) 33/204 (16.18%) 0.249
p-Value 0.567 0.102 0.4671
30 min/d moderate intensity physical activity
Baseline 114/289 (39.45%) 96/284 (33.80%) 0.146
12 mo 96/222 (43.24%) 90/198 (45.45%) 0.551
p-Value 0.498 0.005 0.1081
5% reduction in body weight at 12 mo 43/228 (18.86%) 43/206 (20.87%) 0.599
Total number of goals achieved at 12 mo (missing excluded)2
N 219 197
Number of goals 0.89 1.02 0.201
Total number of goals achieved at 12 mo (missing replaced)3
N 289 284
Number of goals 0.69 0.73 0.612
Data presented as n/N (percent) unless otherwise indicated.
1p-Value for the Wald chi-squared test of the time by group interaction.
2Participants with one or more missing data points excluded.
3Missing data replaced with non-achievement of goal.
doi:10.1371/journal.pmed.1002092.t005
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geographical catchment areas. Only 191 women responded to the NGDR invitation, and 149 of
those subsequently agreed to participate in the intervention, resulting in a penetration rate of
4%, which is low. The implementation metric for MAGDA-DPP had a low level for frequency
of sessions (32% of the number delivered within the US-DPP), a moderate level for duration
(6–12 mo), and a high level for theoretical fidelity (standard curriculum and quality assurance
measures implemented). The participation metric, based on enrolment of invited individuals,
was low (26%) and reflects the challenge of engaging women in the intervention. The measures
for PIPE effectiveness were all low: proportion of successful participants, average weight loss, and
diabetes risk reduction (indirect, assessed against achievement of the five lifestyle modification
goals adopted from the FIN-DPS, which are inversely associated with diabetes incidence [5]).
Among those randomised to the intervention (n = 284), 66% (n = 188) completed at least
the individual session; specifically, 53% met the program minimum exposure definition of
completing the individual session and one or more group sessions (n = 149), 34% had no expo-
sure to the intervention (n = 96), 13% completed only the individual session (n = 37), and only
10% completed the individual session and all five group sessions (n = 28). Pregnancy rates and
subsequent ineligibility for those completing the minimum intervention (11%, 16/149) and
non-completers (14%, 16/135) were similar (p = 0.852). Group facilitators spent an average of
18 min per participant arranging intervention sessions and reminding participants. Despite an
average of four attempts at contact made by facilitators via phone call or text message, 31% of
women failed to attend a single session. To achieve the minimum intervention exposure (1
individual session and1 group session), facilitators made on average ten contacts (mean total
duration 20 min). Group facilitators made on average three contacts (mean total duration 8
min) to ensure attendance at a single session.
Discussion
This study of a postnatal lifestyle intervention in women with gestational diabetes achieved a 1-kg
weight difference compared with the control group. This difference is potentially significant for dia-
betes prevention, but the participation rate was low, reflecting how difficult it was to engage women
in this cohort in the first year after the birth of their child. We found that, on average, women ran-
domised to the MAGDA-DPP intervention group showed no postnatal weight gain, in contrast to
women in the usual care group, who continued to gain weight over the 12-mo study period. The
changes over 12 mo in the other two primary outcomes, the diabetes risk measures fasting blood
glucose and waist circumference, were not significantly different for women in the intervention ver-
sus the control group. Intervention participants did show initial significant weight loss and
improvements in their waist circumference and fasting blood glucose following the intensive com-
ponent of the intervention, but these benefits were for the most part lost at 12 mo. This phenome-
non is common amongst lifestyle modification programs and is a well-noted challenge in diabetes
prevention in general [25,38,39] and in this population in specific [7,25,40,41]. Recruiting and
delivering an intervention within this population of women with young families proved challeng-
ing, and our outcomes are similar to those recently reported by other studies [22,25,41].
Obesity is one of the strongest modifiable risk factors for T2DM development [5,42], and
postnatal weight gain is a key risk factor for women [16,43], especially women with previous
GDM [12,44]. Australian women typically gain 650 g annually [45], and the women in the
MAGDA-DPP usual care group were no different (720 g average). The US Agency for Health-
care Research and Quality recently identified a 0.5-kg between-group weight gain difference as
significant [46], and similarly the US Community Preventive Services Task Force found that
even low levels of weight loss are effective in reducing T2DM risk [47]. Clinical significance has
been attributed to a ~1-kg weight difference over time for cardiovascular disease [48] and
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T2DM [43], amongst other diseases. Wang and colleagues modelled a similar weight change
within the US population and estimated that 2 million diabetes cases could be avoided with
this small change [49]. Given that postnatal weight retention increases diabetes risk [11] and
that guidelines recommend postnatal weight management [31,50,51], our findings could be
interpreted as supporting the potential for a low intensity program to address postnatal weight
retention and therefore lower diabetes risk. We would argue that our findings represent an
issue of low penetration and participation in this target group, resulting in low effectiveness.
The number of reported DPPs specifically designed for women with prior GDM has risen
exponentially, but their effectiveness in reducing diabetes risk has been low to date. A recent
meta-analysis [41] found that no significant reduction in fasting blood glucose or any signifi-
cant impact on weight loss occurred in DPPs of6 mo duration. When the analysis was
expanded to interventions of 12 mo duration, a significant difference in weight change of −1.06
kg (95% CI −1.68, −0.44) was seen, but this was driven by a single interim results publication
for a study whose full intervention results have not been published [20]. It is clear that for effec-
tive weight loss within DPPs, high session frequency and longer program duration and fidelity
are needed [37]. This presents a challenge for women with young families, who commonly cite
a lack of time as a major barrier to engagement [17]. Nevertheless, a lower frequency of ses-
sions can be effective for diabetes prevention—when delivered over longer periods of time and
where penetration and participation rates are higher [37,47]—which is important when look-
ing to sustainability or scaling up a program for health service delivery.
Central to the issue of penetration and participation is the design of randomised trials,
which leads to the recruitment of highly selective populations. One of the largest DPPs in
women with previous GDM comes from a study by Ratner and colleagues [7]; systematic
reviews consistently [41,52,53] identify this study as high-quality evidence for the role of a
DPP in this population, but the generalisability of the results from the population recruited is
rarely discussed. Participants (n = 350) were mothers with IGT who were on average 43 y old,
obese (with a mean BMI of 34.2 kg/m2), and with 12 y since their index GDM pregnancy.
Clearly, their diabetes risk was higher, their child care demands lower, and the chance of
engagement greater. In contrast, MAGDA-DPP mothers were 10 y younger, with BMI averag-
ing in the overweight range, and only 2% had IGT. It is to be expected that their diabetes risk
and their risk perception were likely to be quite different from those of Ratner et al.’s partici-
pants [7]. The recently published GEM trial [25] provides us with a more real-world perspec-
tive on the comparative effectiveness at the health service level. The population of the GEM
trial (n = 2,280) was similar to that of MAGDA-DPP, but the trial’s penetration and participa-
tion was high as a result of the intervention being embedded as usual care within 22 rando-
mised medical facilities and using telephone health coaching. The trial’s 12-mo weight loss
outcomes showed significantly less postpartum weight retention in the intervention partici-
pants and a −0.64 kg weight difference between the intervention and control groups (95% CI
−1.13, −0.14), lending support to our findings being more in line with real-world outcomes.
There are some lessons to be learnt from the factors contributing to the low effect size seen.
The relatively low intervention engagement in MAGDA-DPP is reflected in an accordingly low
level of behavioural change and resulting weight change. Attending and completing weight loss
interventions are known correlates to achieving weight loss [54,55]; when people leave a pro-
gram early, their skills and coping strategies for achieving and sustaining weight loss are likely
to be underdeveloped [56,57]. Risk perception is another important influence on engagement
with lifestyle behaviour change [36]. At the individual session, a risk algorithm was used to
demonstrate the risk of developing diabetes to participants. Risk algorithms are highly age-
dependent; most women were normoglycemic, so it is possible their interpretation was that
they did not need to worry about their risk of diabetes until they were older.
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Strengths of this randomised trial include the length of follow-up after the active interven-
tion, good retention rates, the fidelity measures included in the intervention design, and the
rigorous data collection methodology. Limitations of the MAGDA-DPP study include the low
level of participation in the intervention group sessions along with overall low levels of penetra-
tion and participation, as defined by the PIPE metric [37]. Although relatively extensive con-
sultation work was undertaken prior to MAGDA-DPP implementation (literature review,
qualitative interviews with the population of interest [18], piloting of the program materials in
postnatal women who had gestational diabetes), it is possible that a broader qualitative explora-
tion of issues relating to penetration, compliance, and program delivery may have yielded
stronger engagement and possibly better outcomes. The diabetes risk profiles for MAG-
DA-DPP participants were surprisingly low considering the body of evidence behind GDM
being a strong risk factor for T2DM development [3,11]. At baseline, 10% of MAGDA-DPP
participants were identified as having prediabetes, and their average BMI was only 1 kg/m2
higher than the average Australian woman [58]. It is also possible that those who agreed to par-
ticipate were a lower-risk group, with healthier baseline behaviours. Another possible study
limitation was the study protocol specification of three co-primary endpoints without a plan to
test each at a stringent significance level, or in a hierarchical manner, in order to maintain a
trial-wise type I error rate below, say, the conventional 5%. Our protocol [30] did state that a
“statistically significant change in any one of these three endpoints will be regarded as evidence
of a change in diabetes risk”, and we found a statistically significant difference between the
groups for weight change. The observed magnitude of the difference is similar to the magni-
tudes reported in other studies of lifestyle interventions [25,41], and we believe it is important
to add the result of this study to the accumulating knowledge about the utility of lifestyle modi-
fication programs in mothers with prior GDM.
Translation in Policy and Practice
Our trial explored the effect of offering a DPP in the first year postnatally and showed that it
was ineffective. Telephone- or web-based interventions that can adapt to the time demands of
raising a young family may have more successful participation rates [23,25] and may have the
advantage of being less resource intensive and more suited to scale-up, but it is unlikely that
they will be as effective as programs offered to women with the high-risk characteristics of
those in the study by Ratner et al. [7].
The extent to which the newer GDM diagnostic criteria of the International Association of
Diabetes and Pregnancy Study Groups will affect demand for diabetes prevention services in
not yet known [59], but our finding that the majority of our cohort were at low risk (using the
previous, higher GDM diagnostic cut-offs) suggests that the relative benefit and cost associated
with offering an early postnatal period DPP to all women with a previous GDM pregnancy
does not make it a sensible use of scarce health resources. A better health service approach
might be to improve the currently recommended annual diabetes screening within family med-
icine practice for women with previous GDM, so more women with prediabetes, who are at
high risk, can be identified [50]. This health service approach could be supported by a reminder
system within a national GDM registry, the NGDR being the current Australian example, and
women with prediabetes could be more selectively targeted for recruitment into an appropriate
DPP.
Conclusions
Our results show that a low intensity, group-delivered DPP was superior to usual care in pre-
venting postnatal weight gain in a cohort of women with previous GDM. However, the level of
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engagement was low, and DPPs may need to be offered at other time points after pregnancy.
Further research on engagement is required, including participant input into the design of
interventions, and a more effective option may be to follow up women with previous GDM
until they show IGT or HbA1c levels in the prediabetes range before offering entry to a DPP.
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